{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:59:37Z","timestamp":1790258377477,"version":"4.1.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41375-026-03085-z","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:01:15Z","timestamp":1785319275000},"page":"2118-2126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stuck in traffic: CART cells targeting the tumor microenvironment in hematological malignancies, current advances and future perspectives"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6499-4655","authenticated-orcid":false,"given":"Jennifer Meyer","family":"Feigin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth L.","family":"Siegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2767-3830","authenticated-orcid":false,"given":"Saad S.","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"3085_CR1","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, June C. From concept to cure: The evolution of CAR-T cell therapy. Mol Ther. 2025;33:2123\u201340.","journal-title":"Mol Ther"},{"key":"3085_CR2","unstructured":"Center for Biologics Evaluation and Research. Approved Cellular and Gene Therapy Products [Internet]. U.S. Food and Drug Administration. FDA [cited 6Mar2025]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products; 2025"},{"key":"3085_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"3085_CR4","unstructured":"Center for Biologics Evaluation and Research. CAR T Cells: Engineering Patients\u2019 Immune Cells to Treat Their Cancers [Internet]. U.S. Food and Drug Administration. FDA [cited 26Feb2025]. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells; 2025."},{"key":"3085_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ejh.14101","volume":"112","author":"A Mishra","year":"2024","unstructured":"Mishra A, Maiti R, Mohan P, Gupta P. Antigen loss following CAR-T cell therapy: Mechanisms, implications, and potential solutions. Eur J Haematol. 2024;112:211\u201322.","journal-title":"Eur J Haematol"},{"key":"3085_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2020-137650","volume":"136","author":"N Leblay","year":"2020","unstructured":"Leblay N, Maity R, Barakat E, McCulloch S, Duggan P, Jimenez-Zepeda V, et al. Cite-seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or bites immunotherapy. Blood. 2020;136:11\u20132.","journal-title":"Blood"},{"key":"3085_CR7","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"EJ Orlando","year":"2018","unstructured":"Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24:1504\u20136.","journal-title":"Nat Med"},{"key":"3085_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1182\/blood-2021-150923","volume":"138","author":"DT Melnekoff","year":"2021","unstructured":"Melnekoff DT, Ghodke-Puranik Y, Van Oekelen O, Aleman A, Upadhyaya B, Sebra R, et al. Single-cell profiling reveals contribution of tumor extrinsic and intrinsic factors to BCMA-targeted CAR-T cell efficacy in multiple myeloma. Blood. 2021;138:326.","journal-title":"Blood"},{"key":"3085_CR9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","volume":"37","author":"A Alarcon Tomas","year":"2023","unstructured":"Alarcon Tomas A, Fein JA, Fried S, Flynn JR, Devlin SM, Fingrut WB, et al. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma. Leukemia. 2023;37:154\u201363.","journal-title":"Leukemia"},{"key":"3085_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16160-5","volume":"11","author":"E Zah","year":"2020","unstructured":"Zah E, Nam E, Bhuvan V, Tran U, Ji BY, Gosliner SB, et al. Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun. 2020;11:2283.","journal-title":"Nat Commun"},{"key":"3085_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51978-3","volume":"15","author":"CM Stewart","year":"2024","unstructured":"Stewart CM, Siegler EL, Sakemura RL, Cox MJ, Huynh T, Kimball B, et al. IL-4 drives exhaustion of CD8(+) CART cells. Nat Commun. 2024;15:7921.","journal-title":"Nat Commun"},{"key":"3085_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw9414","volume":"11","author":"H Qin","year":"2019","unstructured":"Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, et al. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci Transl Med. 2019;11:eaaw9414.","journal-title":"Sci Transl Med"},{"key":"3085_CR13","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/s41375-022-01572-7","volume":"36","author":"MJ Cox","year":"2022","unstructured":"Cox MJ, Manriquez Roman C, Tapper EE, Siegler EL, Chappell D, Durrant C, et al. GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. Leukemia. 2022;36:1635\u201345.","journal-title":"Leukemia"},{"key":"3085_CR14","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1158\/2326-6066.CIR-22-0254","volume":"11","author":"RL Sakemura","year":"2023","unstructured":"Sakemura RL, Hefazi M, Cox MJ, Siegler EL, Sinha S, Hansen MJ, et al. AXL inhibition improves the antitumor activity of chimeric antigen receptor T cells. Cancer Immunol Res. 2023;11:1222\u201336.","journal-title":"Cancer Immunol Res"},{"key":"3085_CR15","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"key":"3085_CR16","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.3324\/haematol.2018.195396","volume":"104","author":"D Forte","year":"2019","unstructured":"Forte D, Krause DS, Andreeff M, Bonnet D, M\u00e9ndez-Ferrer S. Updates on the hematologic tumor microenvironment and its therapeutic targeting. Haematologica. 2019;104:1928\u201334.","journal-title":"Haematologica"},{"key":"3085_CR17","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/1535-7163.MCT-21-0506","volume":"22","author":"NE Olson","year":"2023","unstructured":"Olson NE, Ragan SP, Reiss DJ, Thorpe J, Kim Y, Abramson JS, et al. Exploration of tumor biopsy gene signatures to understand the role of the tumor microenvironment in outcomes to lisocabtagene maraleucel. Mol Cancer Ther. 2023;22:406\u201318.","journal-title":"Mol Cancer Ther"},{"key":"3085_CR18","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med. 2022;28:1872\u201382.","journal-title":"Nat Med"},{"key":"3085_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s11684-022-0972-8","volume":"17","author":"Z Yan","year":"2023","unstructured":"Yan Z, Li L, Fu D, Wu W, Qiao N, Huang Y, et al. Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy. Front Med. 2023;17:699\u2013713.","journal-title":"Front Med"},{"key":"3085_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","volume":"18","author":"DF Stroncek","year":"2016","unstructured":"Stroncek DF, Ren J, Lee DW, Tran M, Frodigh SE, Sabatino M, et al. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. Cytotherapy. 2016;18:893\u2013901.","journal-title":"Cytotherapy"},{"key":"3085_CR21","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"3085_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1182\/blood-2019-126218","volume":"134","author":"SS Neelapu","year":"2019","unstructured":"Neelapu SS, Rossi JM, Jacobson CA, Locke FL, Miklos DB, Reagan PM, et al. CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-Axi-Cel. Blood. 2019;134:203.","journal-title":"Blood"},{"key":"3085_CR23","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak \u00d6, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545\u201354.","journal-title":"N Engl J Med"},{"key":"3085_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"3085_CR25","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/JCI86721","volume":"126","author":"P Kebriaei","year":"2016","unstructured":"Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016;126:3363\u201376.","journal-title":"J Clin Invest"},{"key":"3085_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018;378:449\u201359.","journal-title":"N Engl J Med"},{"key":"3085_CR27","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3389\/fonc.2019.00767","volume":"9","author":"Y Cao","year":"2019","unstructured":"Cao Y, Lu W, Sun R, Jin X, Cheng L, He X, et al. Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma. Front Oncol. 2019;9:767.","journal-title":"Front Oncol"},{"key":"3085_CR28","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022;386:640\u201354.","journal-title":"N Engl J Med"},{"key":"3085_CR29","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","volume":"35","author":"ME Dourthe","year":"2021","unstructured":"Dourthe ME, Rabian F, Yakouben K, Chevillon F, Cabannes-Hamy A, M\u00e9chinaud F, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia. 2021;35:3383\u201393.","journal-title":"Leukemia"},{"key":"3085_CR30","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s43018-024-00763-8","volume":"5","author":"M Rade","year":"2024","unstructured":"Rade M, Grieb N, Weiss R, Sia J, Fischer L, Born P, et al. Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma. Nat Cancer. 2024;5:1318\u201333.","journal-title":"Nat Cancer"},{"key":"3085_CR31","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688\u2013700.","journal-title":"Blood"},{"key":"3085_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai Y-T, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12:868.","journal-title":"Nat Commun"},{"key":"3085_CR33","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8:1219\u201326.","journal-title":"Cancer Discov"},{"key":"3085_CR34","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322\u201331.","journal-title":"Blood"},{"key":"3085_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s10555-024-10228-0","volume":"44","author":"TJ Kearl","year":"2024","unstructured":"Kearl TJ, Furqan F, Shah NN. CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms. Cancer Metastasis Rev. 2024;44:12.","journal-title":"Cancer Metastasis Rev"},{"key":"3085_CR36","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/1744666X.2024.2349738","volume":"20","author":"A Dreyzin","year":"2024","unstructured":"Dreyzin A, Rankin AW, Luciani K, Gavrilova T, Shah NN. Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy. Expert Rev Clin Immunol. 2024;20:745\u201363.","journal-title":"Expert Rev Clin Immunol"},{"key":"3085_CR37","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021;137:2621\u201333.","journal-title":"Blood"},{"key":"3085_CR38","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","volume":"30","author":"FL Locke","year":"2024","unstructured":"Locke FL, Filosto S, Chou J, Vardhanabhuti S, Perbost R, Dreger P, et al. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nat Med. 2024;30:507\u201318.","journal-title":"Nat Med"},{"key":"3085_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd4344","volume":"6","author":"M Boulch","year":"2021","unstructured":"Boulch M, Cazaux M, Loe-Mie Y, Thibaut R, Corre B, Lema\u00eetre F, et al. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci Immunol. 2021;6:eabd4344.","journal-title":"Sci Immunol"},{"key":"3085_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20488-3","volume":"12","author":"M Bunse","year":"2021","unstructured":"Bunse M, Pfeilschifter J, Bluhm J, Zschummel M, Joedicke JJ, Wirges A, et al. CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin\u2019s lymphoma and tumor-supportive follicular T helper cells. Nat Commun. 2021;12:240.","journal-title":"Nat Commun"},{"key":"3085_CR41","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1182\/blood-2023-180608","volume":"142","author":"M Ponzo","year":"2023","unstructured":"Ponzo M, Drufuca L, Buracchi C, Nucera S, Bugarin C, Rossetti G, et al. Role of Microenvironment in influencing the activity of CD19 CAR T Cells in B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL). Blood. 2023;142:3475.","journal-title":"Blood"},{"key":"3085_CR42","doi-asserted-by":"crossref","unstructured":"Yun K, Sakemura RL, Can I, Gutierrez Ruiz O, Ogbodo EJ, Zhang S, et al. Intrinsic immunosuppressive features of monocytes suppress CAR-T19 through IL-1 pathway modulation in mantle cell lymphoma. Mol Ther Oncol. 2025;33:200985.","DOI":"10.1016\/j.omton.2025.200985"},{"key":"3085_CR43","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","volume":"3","author":"KM Dhodapkar","year":"2022","unstructured":"Dhodapkar KM, Cohen AD, Kaushal A, Garfall AL, Manalo RJ, Carr AR, et al. Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma. Blood Cancer Discov. 2022;3:490\u2013501.","journal-title":"Blood Cancer Discov"},{"key":"3085_CR44","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1182\/blood.2021012811","volume":"139","author":"R Sakemura","year":"2022","unstructured":"Sakemura R, Hefazi M, Siegler EL, Cox MJ, Larson DP, Hansen MJ, et al. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. Blood. 2022;139:3708\u201321.","journal-title":"Blood"},{"key":"3085_CR45","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1182\/blood-2024-201194","volume":"144","author":"A Aleman","year":"2024","unstructured":"Aleman A, Zhao R, Grossman L, Sanawar R, Aluri S, Mohindru M, et al. BCMA CART therapy failure in myeloma is associated with immunosuppressive S100A8\/9 overexpression and can be ameliorated with novel monoclonal antibodies. Blood. 2024;144:589.","journal-title":"Blood"},{"key":"3085_CR46","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","volume":"12","author":"W Li","year":"2023","unstructured":"Li W, Zhang B, Cao W, Zhang W, Li T, Liu L, et al. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing. Exp Hematol Oncol. 2023;12:44.","journal-title":"Exp Hematol Oncol"},{"key":"3085_CR47","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4049\/jimmunol.2001203","volume":"206","author":"AT Baker","year":"2021","unstructured":"Baker AT, Abuwarwar MH, Poly L, Wilkins S, Fletcher AL. Cancer-associated fibroblasts and T cells: from mechanisms to outcomes. J Immunol. 2021;206:310\u201320.","journal-title":"J Immunol"},{"key":"3085_CR48","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3389\/fimmu.2019.01835","volume":"10","author":"L Monteran","year":"2019","unstructured":"Monteran L, Erez N. The Dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol. 2019;10:1835.","journal-title":"Front Immunol"},{"key":"3085_CR49","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1080\/10428194.2016.1263841","volume":"58","author":"AM Staiger","year":"2017","unstructured":"Staiger AM, Duppel J, Dengler MA, van der Kuip H, V\u00f6hringer MC, Aulitzky WE, et al. An analysis of the role of follicular lymphoma-associated fibroblasts to promote tumor cell viability following drug-induced apoptosis. Leuk Lymphoma. 2017;58:1922\u201330.","journal-title":"Leuk Lymphoma"},{"key":"3085_CR50","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20130110","volume":"210","author":"E Tran","year":"2013","unstructured":"Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee C-CR, Restifo NP, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210:1125\u201335.","journal-title":"J Exp Med"},{"key":"3085_CR51","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-23-3841","volume":"30","author":"M Wehrli","year":"2024","unstructured":"Wehrli M, Guinn S, Birocchi F, Kuo A, Sun Y, Larson RC, et al. Mesothelin CAR T cells secreting anti-FAP\/Anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma. Clin Cancer Res. 2024;30:1859\u201377.","journal-title":"Clin Cancer Res"},{"key":"3085_CR52","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1158\/1538-7445.AM2026-1525","volume":"86","author":"OL Gutierrez Ruiz","year":"2026","unstructured":"Gutierrez Ruiz OL, Feigin J, Kimball B, Sakemura RL, Siegler EL, Skeele DA, et al. Abstract 1525: Optimized CART cell therapy to remodel the tumor microenvironment and eliminate GI malignancies. Cancer Res. 2026;86:1525.","journal-title":"Cancer Res"},{"key":"3085_CR53","doi-asserted-by":"publisher","first-page":"6852","DOI":"10.1158\/0008-5472.CAN-18-1750","volume":"78","author":"JD Freedman","year":"2018","unstructured":"Freedman JD, Duffy MR, Lei-Rossmann J, Muntzer A, Scott EM, Hagel J, et al. An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells. Cancer Res. 2018;78:6852\u201365.","journal-title":"Cancer Res"},{"key":"3085_CR54","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nrd.2018.23","volume":"17","author":"M Cully","year":"2018","unstructured":"Cully M. Fibroblast subtype provides niche for cancer stem cells. Nat Rev Drug Discov. 2018;17:163.","journal-title":"Nat Rev Drug Discov"},{"key":"3085_CR55","doi-asserted-by":"crossref","unstructured":"Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol. 2014;6:a021857.","DOI":"10.1101\/cshperspect.a021857"},{"key":"3085_CR56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.coi.2005.11.006","volume":"18","author":"V Chitu","year":"2006","unstructured":"Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol. 2006;18:39\u201348.","journal-title":"Curr Opin Immunol"},{"key":"3085_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1041010","volume":"13","author":"V Plackoska","year":"2022","unstructured":"Plackoska V, Shaban D, Nijnik A. Hematologic dysfunction in cancer: Mechanisms, effects on antitumor immunity, and roles in disease progression. Front Immunol. 2022;13:1041010.","journal-title":"Front Immunol"},{"key":"3085_CR58","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","volume":"25","author":"CH Ries","year":"2014","unstructured":"Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25:846\u201359.","journal-title":"Cancer Cell"},{"key":"3085_CR59","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1038\/s41587-023-01684-0","volume":"41","author":"A Gottschlich","year":"2023","unstructured":"Gottschlich A, Thomas M, Gr\u00fcnmeier R, Lesch S, Rohrbacher L, Igl V, et al. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat Biotechnol. 2023;41:1618\u201332.","journal-title":"Nat Biotechnol"},{"key":"3085_CR60","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2217\/imt-2018-0012","volume":"10","author":"P Zhang","year":"2018","unstructured":"Zhang P, Zhao S, Wu C, Li J, Li Z, Wen C, et al. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages. Immunotherapy. 2018;10:935\u201349.","journal-title":"Immunotherapy"},{"key":"3085_CR61","doi-asserted-by":"crossref","unstructured":"Achkova DY, Beatson RE, Maher J. CAR T-cell targeting of macrophage colony-stimulating factor receptor. Cells. 2022;11:2190.","DOI":"10.3390\/cells11142190"},{"key":"3085_CR62","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1182\/blood-2024-207376","volume":"144","author":"GV Hoffmann","year":"2024","unstructured":"Hoffmann GV, Gottschlich A, Sam J, Gebhardt S, Rohrbacher L, Nandi S, et al. CSF1R Targeting T Cell Engaging Bispecific Antibodies Enable Safe and Efficient Immunotherapies in Acute Myeloid Leukemia. Blood. 2024;144:918.","journal-title":"Blood"},{"key":"3085_CR63","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.omtn.2023.07.020","volume":"33","author":"CA Di Trani","year":"2023","unstructured":"Di Trani CA, Cirella A, Arrizabalaga L, Alvarez M, Bella \u00c1, Fernandez-Sendin M, et al. Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure. Mol Ther Nucleic Acids. 2023;33:599\u2013616.","journal-title":"Mol Ther Nucleic Acids"},{"key":"3085_CR64","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.ccell.2025.05.013","volume":"43","author":"D Stahl","year":"2025","unstructured":"Stahl D, G\u00f6del P, Balke-Want H, Gholamipoorfard R, Segbers P, Tetenborg L, et al. CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma. Cancer Cell. 2025;43:1476\u201394.e10.","journal-title":"Cancer Cell"},{"key":"3085_CR65","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","volume":"52","author":"MEW Logtenberg","year":"2020","unstructured":"Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRP\u03b1 Immune Checkpoint. Immunity. 2020;52:742\u201352.","journal-title":"Immunity"},{"key":"3085_CR66","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","volume":"19","author":"M Feng","year":"2019","unstructured":"Feng M, Jiang W, Kim BYS, Zhang CC, Fu YX, Weissman IL. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019;19:568\u201386.","journal-title":"Nat Rev Cancer"},{"key":"3085_CR67","doi-asserted-by":"crossref","unstructured":"Golubovskaya V, Wu L. Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy. Cancers 2016;8:36.","DOI":"10.3390\/cancers8030036"},{"key":"3085_CR68","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI81603","volume":"126","author":"K Weiskopf","year":"2016","unstructured":"Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest. 2016;126:2610\u201320.","journal-title":"J Clin Invest"},{"key":"3085_CR69","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","volume":"630","author":"SA Yamada-Hunter","year":"2024","unstructured":"Yamada-Hunter SA, Theruvath J, McIntosh BJ, Freitas KA, Lin F, Radosevich MT, et al. Engineered CD47 protects T cells for enhanced antitumour immunity. Nature. 2024;630:457\u201365.","journal-title":"Nature"},{"key":"3085_CR70","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/blood.2022016101","volume":"141","author":"MM Dacek","year":"2023","unstructured":"Dacek MM, Kurtz KG, Wallisch P, Pierre SA, Khayat S, Bourne CM, et al. Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRP\u03b1 checkpoint blocker. Blood. 2023;141:2003\u201315.","journal-title":"Blood"},{"key":"3085_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54129-w","volume":"15","author":"TA Martins","year":"2024","unstructured":"Martins TA, Kaymak D, Tatari N, Gerster F, Hogan S, Ritz MF, et al. Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPgamma-derived CD47 blocker. Nat Commun. 2024;15:9718.","journal-title":"Nat Commun"},{"key":"3085_CR72","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","volume":"8","author":"G Ledergor","year":"2024","unstructured":"Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, et al. CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2024;8:3562\u201375.","journal-title":"Blood Adv"},{"key":"3085_CR73","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022;28:1848\u201359.","journal-title":"Nat Med"},{"key":"3085_CR74","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1021\/acsptsci.4c00156","volume":"7","author":"S Bhattacharya","year":"2024","unstructured":"Bhattacharya S, Paraskar G, Jha M, Gupta GL, Prajapati BG. Deciphering regulatory T-cell dynamics in cancer immunotherapy: mechanisms, implications, and therapeutic innovations. ACS Pharmacol Transl Sci. 2024;7:2215\u201336.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3085_CR75","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/febs.17326","volume":"292","author":"Y Sun","year":"2025","unstructured":"Sun Y, Liu J, Zhan D, Wei J, XianShi L, Zhang R, et al. Depletion of Tregs from CD4(+) CAR-T cells enhances the tumoricidal effect of CD8(+) CAR-T cells in anti-CD19 CAR-T therapy. FEBS J. 2025;292:1904\u201319.","journal-title":"FEBS J"},{"key":"3085_CR76","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cmet.2025.04.008","volume":"37","author":"C Niu","year":"2025","unstructured":"Niu C, Wei H, Pan X, Wang Y, Song H, Li C, et al. Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming. Cell Metab. 2025;37:1426\u201341.e7.","journal-title":"Cell Metab"},{"key":"3085_CR77","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12:180\u201390.","journal-title":"Nat Rev Immunol"},{"key":"3085_CR78","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity. 2016;44:380\u201390.","journal-title":"Immunity"},{"key":"3085_CR79","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.omto.2021.03.014","volume":"21","author":"X Chen","year":"2021","unstructured":"Chen X, Yang S, Li S, Qu Y, Wang HY, Liu J, et al. Secretion of bispecific protein of anti-PD-1 fused with TGF-\u03b2 trap enhances antitumor efficacy of CAR-T cell therapy. Mol Ther Oncolytics. 2021;21:144\u201357.","journal-title":"Mol Ther Oncolytics"},{"key":"3085_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107352","volume":"208","author":"B Spokeviciute","year":"2024","unstructured":"Spokeviciute B, Kholia S, Brizzi MF. Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy. Pharmacol Res. 2024;208:107352.","journal-title":"Pharmacol Res"},{"key":"3085_CR81","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.ymthe.2020.12.033","volume":"29","author":"MJ Cox","year":"2021","unstructured":"Cox MJ, Lucien F, Sakemura R, Boysen JC, Kim Y, Horvei P, et al. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. Mol Ther. 2021;29:1529\u201340.","journal-title":"Mol Ther"},{"key":"3085_CR82","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.ymthe.2021.01.020","volume":"29","author":"K Dooley","year":"2021","unstructured":"Dooley K, McConnell RE, Xu K, Lewis ND, Haupt S, Youniss MR, et al. A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties. Mol Ther. 2021;29:1729\u201343.","journal-title":"Mol Ther"},{"key":"3085_CR83","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","volume":"350","author":"J-e Zhou","year":"2022","unstructured":"Zhou J-e, Sun L, Jia Y, Wang Z, Luo T, Tan J, et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. J Control Release. 2022;350:298\u2013307.","journal-title":"J Control Release"},{"key":"3085_CR84","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1158\/1538-7445.AM2024-3841","volume":"84","author":"O Sirpilla","year":"2024","unstructured":"Sirpilla O, Sakemura RL, Can I, Huynh TN, GIrsch JH, Roman CM, et al. Abstract 3841: tumor-derived microRNA125a induces CART cell apoptosis and failure in B cell malignancies. Cancer Res. 2024;84:3841.","journal-title":"Cancer Res"},{"key":"3085_CR85","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2024-206731","volume":"144","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Huang M, Liu T, Cheng Y, Li D, Cao Y, et al. Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles. Blood. 2024;144:3419.","journal-title":"Blood"},{"key":"3085_CR86","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.omto.2017.12.003","volume":"8","author":"G Kueberuwa","year":"2018","unstructured":"Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins RE, Gilham DE. CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity. Mol Ther Oncolytics. 2018;8:41\u201351.","journal-title":"Mol Ther Oncolytics"},{"key":"3085_CR87","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/leu.2014.215","volume":"29","author":"HJ Pegram","year":"2015","unstructured":"Pegram HJ, Purdon TJ, van Leeuwen DG, Curran KJ, Giralt SA, Barker JN, et al. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia. 2015;29:415\u201322.","journal-title":"Leukemia"},{"key":"3085_CR88","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1182\/blood.2023022293","volume":"144","author":"BD Ng","year":"2024","unstructured":"Ng BD, Rajagopalan A, Kousa AI, Fischman JS, Chen S, Massa A, et al. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model. Blood. 2024;144:171\u201386.","journal-title":"Blood"},{"key":"3085_CR89","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1182\/blood.2025029532","volume":"146","author":"MB Geyer","year":"2025","unstructured":"Geyer MB, DeWolf S, Mi X, Weis K, Shaffer BC, Cadzin B, et al. CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia. Blood. 2025;146:3163\u201374.","journal-title":"Blood"},{"key":"3085_CR90","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1200\/JCO.2024.42.16_suppl.7004","volume":"42","author":"J Svoboda","year":"2024","unstructured":"Svoboda J, Landsburg DJ, Nasta SD, Barta SK, Chong EA, Lariviere MJ, et al. Safety and efficacy of armored huCART19-IL18 in patients with relapsed\/refractory lymphomas that progressed after anti-CD19 CAR T cells. J Clin Oncol. 2024;42:7004.","journal-title":"J Clin Oncol"},{"key":"3085_CR91","doi-asserted-by":"crossref","unstructured":"Noh KE, Lee JH, Choi SY, Jung NC, Nam JH, Oh JS, et al. TGF-\u03b2\/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma. Int J Mol Sci. 2021;22:8706.","DOI":"10.3390\/ijms22168706"},{"key":"3085_CR92","first-page":"A406","volume":"10","author":"JJ Zhu","year":"2022","unstructured":"Zhu JJ, DSouza C, Qin V, Thio N, Kershaw M, Trapani J, et al. 385 Engineering a TGF-\u03b2 switch receptor enhances CAR-T cell function in a suppressive TGF-\u03b2-enriched tumor microenvironment. J Immunother Cancer. 2022;10:A406.","journal-title":"J Immunother Cancer"},{"key":"3085_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101421","volume":"5","author":"LF Prinz","year":"2024","unstructured":"Prinz LF, Riet T, Neureuther DF, Lennartz S, Chrobok D, H\u00fcbbe H, et al. An anti-CD19\/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80\/86-upregulated DLBCL. Cell Rep Med. 2024;5:101421.","journal-title":"Cell Rep Med"},{"key":"3085_CR94","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s12967-021-03146-0","volume":"19","author":"K Alishah","year":"2021","unstructured":"Alishah K, Birtel M, Masoumi E, Jafarzadeh L, Mirzaee HR, Hadjati J, et al. CRISPR\/Cas9-mediated TGF\u03b2RII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro. J Trans Med. 2021;19:482.","journal-title":"J Trans Med"},{"key":"3085_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.832645","volume":"13","author":"LM Alabanza","year":"2022","unstructured":"Alabanza LM, Xiong Y, Vu B, Webster B, Wu D, Hu P, et al. Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-\u03b2. Front Immunol. 2022;13:832645.","journal-title":"Front Immunol"},{"key":"3085_CR96","doi-asserted-by":"publisher","first-page":"34341","DOI":"10.18632\/oncotarget.9114","volume":"7","author":"ER Suarez","year":"2016","unstructured":"Suarez ER, de Chang K, Sun J, Sui J, Freeman GJ, Signoretti S, et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016;7:34341\u201355.","journal-title":"Oncotarget"},{"key":"3085_CR97","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1158\/2326-6066.CIR-19-0734","volume":"8","author":"YJ Xie","year":"2020","unstructured":"Xie YJ, Dougan M, Ingram JR, Pishesha N, Fang T, Momin N, et al. Improved antitumor efficacy of chimeric antigen receptor t cells that secrete single-domain antibody fragments. Cancer Immunol Res. 2020;8:518\u201329.","journal-title":"Cancer Immunol Res"},{"key":"3085_CR98","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","volume":"22","author":"Y Guo","year":"2021","unstructured":"Guo Y, Xie YQ, Gao M, Zhao Y, Franco F, Wenes M, et al. Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity. Nat Immunol. 2021;22:746\u201356.","journal-title":"Nat Immunol"},{"key":"3085_CR99","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","volume":"634","author":"B Feng","year":"2024","unstructured":"Feng B, Bai Z, Zhou X, Zhao Y, Xie Y-Q, Huang X, et al. The type 2 cytokine Fc\u2013IL-4 revitalizes exhausted CD8+ T cells against cancer. Nature. 2024;634:712\u201320.","journal-title":"Nature"},{"key":"3085_CR100","doi-asserted-by":"crossref","unstructured":"Yamaguchi Y, Gibson J, Ou K, Lopez LS, Ng RH, Leggett N, et al. PD-L1 blockade restores CAR T cell activity through IFN-gamma-regulation of CD163+ M2 macrophages. J Immunother Cancer. 2022;10:e004400.","DOI":"10.1136\/jitc-2021-004400"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03085-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03085-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03085-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:06:15Z","timestamp":1790255175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03085-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":100,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3085"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03085-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SSK is an inventor on patents in the field of CAR immunotherapy that are licensed to Novartis (through an agreement between Mayo Clinic, University of Pennsylvania, and Novartis), Humanigen\/Taran (through Mayo Clinic), MustangBio (through Mayo Clinic), and Chymal (through Mayo Clinic). JMF, ELS, and SSK are inventors on patents licensed to Immix (through Mayo Clinic). SSK receives research funding from Kite, Gilead, Juno, BMS, Novartis, Humanigen\/Taran, MorphoSys, Tolero, Sunesis\/Viracta, LifEngine Animal Health Laboratories Inc, and Lentigen. SSK has participated in advisory meetings with Kite\/Gilead, Calibr, Luminary Therapeutics, Humanigen, Juno\/BMS, Capstan Bio, Carisma, and Novartis. SSK has served on the data safety and monitoring board with Humanigen. SSK has served as a consultant for Torque, Calibr, Novartis, Capstan Bio, and Humanigen. JMF holds equity in Adimab, Bristol Myers Squibb, and Regeneron outside the submitted work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Ethics"}}]}}